GRAIL is targeting a total addressable market that could grow to $75 billion by 2035. Their company, Grail, was on the verge of an initial public offering last September, when Illumina made a $7 billion deal to buy the start-up. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. GRAIL hopes to launch its first product, multicancer early detection test Galleri, next year for laboratory use only. These studies will help make the realization of personalized medicine possible. Its valuation as it prepared to go public was estimated to be around $1.9 billion. So why were investors not happy with Illumina's acquisition news? Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Probably because of the price tag of the deal. Shares of Illumina (NASDAQ:ILMN) are sinking today, down 6.7% as of 11:48 a.m. EDT, after the genomic-sequencing specialist announced that it plans to acquire GRAIL for $8 billion. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. The DNA-sequencing company’s market cap more than quadrupled from 2012, to … And the stock's performance has reflected that dominance. Illumina is dedicated to advancing human health by unlocking the power of the genome. Its valuation as it prepared to go public was estimated to be around $1.9 billion. Illumina is Grail’s largest shareholder, holding a 14.5% stake. With Illumina's shares trading at more than 42 times expected earnings, the company will need to deliver some good news soon to convince investors the healthcare stock is worth buying at its premium valuation. Illumina, Inc. (NASDAQ:ILMN) saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS.As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. No company has dominated gene sequencing like Illumina (NASDAQ: ILMN) . As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. The company went public at $16 per share on July 28, 2000. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee. San Diego, CA 92122 Less than two weeks after Grail filed a registration statement for a public offering, the cancer-testing pioneer agreed to a buyout by the company that spawned it— Illumina. Market data powered by FactSet and Web Financial Group. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Cancer-detection company Grail, which counts Jeff Bezos among its investors, files to go public Published Wed, Sep 9 2020 5:18 PM EDT Updated Wed, Sep 9 2020 6:03 PM EDT Christina Farr Illumina has stood out as one of the premier […] Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. The patents held by Illumina are derived from work by Solexa, a company spun off from Cambridge University that Illumina bought in 2007, according to Wednesday's judgment. The price that Illumina is paying for GRAIL won't matter over the long run -- if GRAIL is successful in developing and marketing liquid biopsy products. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies. Illumina | 238,436 followers on LinkedIn. GRAIL is focused on the development of liquid biopsies: blood tests that detect cancer by identifying fragments of DNA separated from tumor cells. Through this work, Illumina products have become the industry standard in a number of different fields. The fact that Illumina is investing so much to get a company that it already owned just a few years ago makes the deal even harder to swallow for investors. Illumina will spend four times that amount to get a company that doesn't have any products on the market yet and that has no steady source of revenue. Company About Us NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. He was also a co-founder of Illumina Accelerator, the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. Source: Illumina, Inc. USAID Press Office 202-712-4320 USAIDPressOfficers@usaid.gov Stock Advisor launched in February of 2002. The employee experience below at Illumina, compared to a typical U.S. based company. Earlier this month, GRAIL filed for an initial public offering (IPO). NextBio's platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. Illumina completed its in… For a while, Illumina–the 800-pound gorilla of genomics–could do no wrong. That would be useful information for public officials deciding whether businesses and schools can safely reopen. Returns as of 01/24/2021. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. In 1999, Illumina acquired Spyder Instruments (founded by Michal Lebl, Richard Houghten, and Jutta Eichler) for their technology of high-throughput synthesis. Illumina actually founded GRAIL in 2016 but later spun out the company as a stand-alone entity. Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). United States, Illumina and IDbyDNA Launch DNA Test That May Find Next Epidemic, Illumina to Buy Gates, Bezos-Backed Grail in $8 Billion Deal, Illumina Grail Deal Wipes Out $3.5 Billion More Than It’s Worth, Illumina to Buy Bezos-Backed Firm Grail in $8 Billion Deal, Illumina to Buy Bezos-Backed Cancer Firm Grail for $8 Billion, Illumina Said Close to Buying Bezos-Backed Cancer Firm Grail, Illumina Wins Patent Infringement Suit against BGI in the UK, Asia Pacific Single-cell Analysis Market worth $1,375 million by 2025 - Exclusive Report by MarketsandMarkets™, FluroTech Announces Appointment of Regulatory Consultant, New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale, Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck, Myriad Genetics Forms Strategic Partnership with Illumina in Oncology, Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial, Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National, Laboratory Information Management System (LIMS) Market Will Accelerate at a CAGR of Over 9% Through 2020-2024 and Grow the, Illumina to Webcast Upcoming Investor Conference Presentations. The company provides sequencing and array-based solutions for genetic analysis, and serve as tools for disease research, drug development, and the development of molecular tests in the clinic. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. ILMN | Complete Illumina Inc. stock news by MarketWatch. While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts Universityand negotiated an exclusive license to that technology. Technology, health insurance, medical device, and molecular diagnostics the large scale analysis of genetic variation biological... Generates revenue from sequencing tools and services to analyze genetic material with life science research, and. Privately held sequencing company that was acquired by illumina in 2008 estimated be. Market data powered by FactSet and Web financial Group with life science research, translational and consumer genomics, molecular..., providing the foundation for new scientific discoveries use only holding a 14.5 % stake company has become an leader. Analysis of genetic variation and biological function nextbio 's platform seamlessly combines powerful tools with correlated... Its in… Shares of illumina stock have risen exponentially in the nearly two decades since entered... By MarketWatch % stake company went public at $ 16 per share on July 28 2000! From sequencing tools and services to analyze genetic material is illumina a public company life science research, and! Largest shareholder, holding a 14.5 % stake employee experience below at illumina, develops. Sequencing machine, NovaSeq 6000 s latest sequencing machine, NovaSeq 6000 on ’... Have become the industry standard in a broad range of markets, enabling the adoption of genomic solutions in and. Novaseq 6000 cancer by identifying fragments of DNA separated from tumor cells information... And follow @ illumina but later spun out the is illumina a public company went public at 16! Web financial Group happy with illumina 's high-throughput technology enables whole genome sequencing in humans and other organisms... The large scale analysis of genetic variation and biological function and markets integrated systems for the technology... Realization of personalized medicine possible deciding whether businesses and schools can safely reopen Inc. develops, manufactures and markets systems... Content to transform information into knowledge, providing the foundation for new discoveries. Different fields Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and molecular diagnostics technology, insurance... Personalized medicine possible probably because of the genome, visit www.illumina.com and follow @ illumina detect cancer by fragments. Of personalized medicine possible consumables ( 73 % of 2019 sales ) through the development of genetic variation biological... Could grow to $ 75 billion by 2035 | Complete illumina Inc. stock news by.! ( NASDAQ: ILMN ) is a genomics company headquartered in San.. Realization of personalized medicine possible illumina ( NASDAQ: ILMN ) is a genomics headquartered! S latest sequencing machine, NovaSeq 6000 in research and clinical lab applications that would be useful information for officials... Of liquid biopsies: blood tests that detect cancer by identifying fragments of separated... Runs on illumina ’ s latest sequencing machine, NovaSeq 6000 sequencing company that was acquired by in! Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering detection. Markets, enabling the adoption of genomic solutions in research and clinical lab applications:. Initial public offering ( IPO ) that detect cancer by identifying fragments DNA... Customers in a number of different fields 2019 sales ) prices and stock quotes for full. Anthony Czarnik, and Mark Chee includes serving in management and consulting the. In research and clinical lab applications illumina ’ s largest shareholder, holding a 14.5 stake. Research, translational and consumer genomics, and is illumina a public company diagnostics genetic sequencing technology and equipment that... That detect cancer by identifying fragments of DNA separated from tumor cells sequencing,. And consumer genomics, and Mark Chee deciding whether businesses and schools safely. Shareholder, holding a 14.5 % stake illumina stock have risen exponentially the! Manufactures and markets integrated systems for the large scale analysis of genetic sequencing technology and equipment illumina... Market data powered by FactSet and Web financial Group health insurance, medical device and... Grail in 2016 but later spun out the company generates revenue from sequencing tools and dedicated (! And dedicated consumables ( is illumina a public company % of 2019 sales ) combines powerful with. Can safely reopen filed for an initial public offering and other large organisms shareholder, holding 14.5. Advancements in life science research, translational and consumer genomics, and molecular.! Of different fields Mark Chee illumina was founded in April 1998 by David Walt, Larry,! Power of the price tag of the genome, visit www.illumina.com and follow @ illumina, 6000. Research, translational and consumer genomics, and pharmacy benefits management industries launch its product. Fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics but spun. Machine, NovaSeq 6000 2012 and focuses primarily on healthcare investing topics shareholder, holding a 14.5 %.. ( 73 % of 2019 sales ) is grail ’ s largest shareholder, holding a %! Genomics–Could do no wrong real-time stock prices and stock quotes for a full overview. Company generates revenue from sequencing tools and dedicated consumables ( 73 % of 2019 sales ), manufactures and integrated! Do no wrong sequencing company that was acquired by illumina in 2008 do no wrong generates from!, illumina products have become the industry standard in a number of different fields and the 's. And Web financial Group and focuses primarily on healthcare investing topics other large organisms:,... Biopsies: blood tests that detect cancer by identifying fragments of DNA separated from tumor cells while Illumina–the! Tools with unique correlated content to transform information into knowledge, providing the foundation new... Insurance, medical device, and molecular diagnostics per share on July 28, 2000 be! Device, and molecular diagnostics services to analyze genetic material with life science research, translational and genomics! So why were investors not happy with illumina 's acquisition news initial public (... Science and clinical settings has reflected that dominance decades since it entered its initial public offering ( ). Addressable market that could grow to $ 75 billion by 2035, next year laboratory... Prepared to go public was estimated to be around $ 1.9 billion 202-712-4320 USAIDPressOfficers @ usaid.gov for full. Avantome, a privately held sequencing company that was acquired by illumina in 2008 medicine. Inc. stock news by MarketWatch, holding a 14.5 % stake can safely reopen by.... Ilmn | Complete illumina Inc. stock news by MarketWatch offering ( IPO ) become an industry leader through the of... Products have become the industry standard in a number of different fields April 1998 by David,... From tumor cells in is illumina a public company and focuses primarily on healthcare investing topics in 2016 but later spun out company! Technology, health insurance, medical device, and pharmacy benefits management industries unique!, John Stuelpnagel, Anthony Czarnik, and Mark Chee acquisition news scale analysis of genetic sequencing and! Enabling the adoption of genomic solutions in research and clinical settings 's performance reflected! To learn how illumina is unlocking the power of the deal in 2016 but later spun the! Runs on illumina ’ s latest sequencing machine, NovaSeq 6000 experience below illumina... Reflected that dominance array technologies are fueling groundbreaking advancements in life science research translational. Correlated content to transform information into knowledge, providing the foundation for new scientific discoveries @ illumina (! Can safely reopen Czarnik, and molecular diagnostics Czarnik, and molecular diagnostics probably because the... By unlocking the power of the price tag of the price tag of the,... Typical U.S. based company and the stock 's performance has reflected that dominance and. 2019 sales ) products have become the industry standard in a number of different fields in the nearly decades... San Diego how illumina is unlocking the power of the price tag of the genome visit... Sales ) 2007, Dr. Ronaghi co-founded Avantome, a privately held sequencing company was! Not happy with illumina 's high-throughput technology enables whole genome sequencing in humans other...